Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.08
- Piotroski Score 6.00
- Grade Hold
- Symbol (EW)
- Company Edwards Lifesciences Corporation
- Price $70.48
- Changes Percentage (0.14%)
- Change $0.1
- Day Low $69.97
- Day High $71.00
- Year High $96.12
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $80.00
- High Stock Price Target $140.00
- Low Stock Price Target $66.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.32
- Trailing P/E Ratio 37.99
- Forward P/E Ratio 37.99
- P/E Growth 37.99
- Net Income $1.40 B
Income Statement
Quarterly
Annual
Latest News of EW
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Wordle Review Answer for Nov. 24, 2024
Explore hints and discussions on today's Wordle puzzle. Be cautious, spoilers ahead! Today's puzzle difficulty is rated moderately challenging with an average of 5 guesses. Learn about featured artist...
By The New York Times | 1 hour ago -
Cher came back from owing $270,000 in back taxes, only to wind up broke again. 6 points about money from her new memoir.
Cher admits to overspending and lacking financial knowledge in her memoir. Despite financial struggles, she found comfort in real estate investments. Cher learned valuable lessons about money manageme...
By Business Insider | 2 hours ago -
'The Interview': K-Pop Trained Rosé to Be 'a Perfect Girl.' Now She's Trying to Be Herself.
K-pop culture is more than just music, it's a phenomenon with devoted fans globally. Rosé, from Blackpink, is breaking out with her solo album, reflecting on her journey as a K-pop idol. The intense ...
By The New York Times | 2 hours ago
